Search Results

Assembly Biosciences, Inc. today announced that it has closed the issuance of shares of its common stock and warrants to Armistice Capital LLC (“Armistice Capital”), a healthcare-focused institutional investor, and Gilead Sciences, Inc. (“Gilead”), in separate equity financings that have resulted in aggregate gross proceeds to Assembly Bio of approximately $12.6 million, before deducting expenses.

Polarean Imaging plc, a commercial-stage medical device leader in advanced Magnetic Resonance Imaging of the lungs, announces the closing of a $12.6 million oversubscribed financing via the Alternative Investment Market of the London Stock Exchange.

The Melanoma Research Alliance, the world’s leading non-profit funder of melanoma research, announced its $12.6 million commitment to fund melanoma research supporting more than 30 scientists at leading academic and medical institutions in the United States and across the globe.

Denali Therapeutics Inc. today announced that the U.S. Food and Drug Administration (FDA) has selected DNL126 for participation in the Support for clinical Trials Advancing Rare disease Therapeutics (START) Pilot Program.

Everest Medicines announced that the Company expects to record a total revenue ranging between RMB124 million and RMB126 million for 2023, according to preliminary review of unaudited management accounts.